AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36650593 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 0
Study 36650593 — intervention group
Group type: COMPARATOR
Intervention: High-PEEP/FiO2 tables
Number of subjects: 0
Study 36650958 — intervention group
Group type: EXPERIMENTAL
Intervention: SET-ULM (Spatial Exploration Test of Upper Limb Mobility)
Number of subjects: 30
Study 36650958 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM)
Number of subjects: 30
Study 36651161 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/week
Number of subjects: 62
Study 36651161 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.20 mg/kg/week
Number of subjects: 62
Study 36651161 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.24 mg/kg/week
Number of subjects: 62
Study 36651161 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.035 mg/kg/day
Number of subjects: 62
Study 36651161 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.067 mg/kg/day
Number of subjects: 62
Study 36651161 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (all doses)
Number of subjects: 62
Study 36651161 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (both doses)
Number of subjects: 62
Study 36651370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoveil (polyglycolic acid)
Number of subjects: 45
Study 36651370 — intervention group
Group type: COMPARATOR
Intervention: TachoSil (collagen sponge)
Number of subjects: 45
Study 36651481 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 18264
Study 36651481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frailty
Number of subjects: 18264
Study 36651481 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 18264
Study 36651481 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-existent MetS with pre-frailty/frailty
Number of subjects: 18264
Study 36651481 — intervention group
Group type: COMPARATOR
Intervention: MetS alone
Number of subjects: 18264
Study 36651601 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic disease-modifying antirheumatic drugs)
Number of subjects: 532
Study 36651624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - 16 1-hour sessions
Number of subjects: 131
Study 36651624 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (duloxetine 30-60 mg/day or escitalopram 10-20 mg/day)
Number of subjects: 131
Study 36651624 — intervention group
Group type: COMPARATOR
Intervention: Both CBT and medication
Number of subjects: 131
Study 36651624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 131
Study 36651624 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 131
Study 36651820 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1.0 mg
Number of subjects: 3534
Study 36651820 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3534
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in general wards (GWs)
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in ICU
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heart failure (AHF)
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory failure (ARF)
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex in general wards (GWs)
Number of subjects: 4499
Study 36651866 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex in ICU
Number of subjects: 4499
Study 36651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment via a rehabilitation program and antiplatelet therapy
Number of subjects: 49
Study 36651955 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV (extracellular volume fraction)
Number of subjects: 49
Study 36651958 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-video mind-body program for stress management and resiliency
Number of subjects: 220
Study 36651961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous V937 (1 × 10) and ipilimumab, up to 8 cycles of V937, median of 6 injections of V937 and 3.5 infusions of ipilimumab
Number of subjects: 11
Study 36651990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein (240 g/day)
Number of subjects: 20
Study 36651990 — intervention group
Group type: COMPARATOR
Intervention: High red and processed meat diet
Number of subjects: 20
Study 36652004 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified serial surgical techniques 'ASTRO'
Number of subjects: 24
Study 36652022 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 61
Study 36652022 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study 36652082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD devices under battery advisory
Number of subjects: 1054
Study 36652106 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI) - individualized single preprandial dose of TI (4-12 U, in 4-U increments) via oral inhalation.
Number of subjects: 27
Study 36652155 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0
Study 36652155 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical local therapies (thermal ablation, hepatic arterial infusion pump (HAIP), stereotactic body radiation therapy (SBRT))
Number of subjects: 0
Study 36652155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0
Study 36652155 — intervention group
Group type: COMPARATOR
Intervention: Metastasis-directed therapy
Number of subjects: 0
Study 36652175 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study 36652175 — intervention group
Group type: COMPARATOR
Intervention: Real-World Clinical Practice (RWCP) treatments
Number of subjects: 0
Study 36652223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study 36652281 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Person's Face IT (YPF), a self-guided web-based intervention
Number of subjects: 71
Study 36652284 — intervention group
Group type: EXPERIMENTAL
Intervention: eOncoNote plus usual methods of communication
Number of subjects: 173
Study 36652284 — intervention group
Group type: COMPARATOR
Intervention: Usual communication only
Number of subjects: 173
Study 36652352 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg twice daily)
Number of subjects: 12211
Study 36652352 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin, 30 mg twice daily)
Number of subjects: 12211
Study 36652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (30 μg)
Number of subjects: 1846
Study 36652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (60 μg)
Number of subjects: 1846
Study 36652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent BA.1 (60 μg)
Number of subjects: 1846
Study 36652353 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (30 μg)
Number of subjects: 1846
Study 36652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (30 μg and 60 μg) and Monovalent BA.1 (60 μg)
Number of subjects: 1846
Study 36652354 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib
Number of subjects: 103
Study 36652465 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 716
Study 36652465 — intervention group
Group type: COMPARATOR
Intervention: Other oral hypoglycemic agents
Number of subjects: 716
Study 36652665 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin
Number of subjects: 54
Study 36652665 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide followed by docetaxel
Number of subjects: 54
Study 36652665 — intervention group
Group type: EXPERIMENTAL
Intervention: High HRD scores (≥ 38)
Number of subjects: 54
Study 36652665 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1/2 mutations
Number of subjects: 54
Study 36652687 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-Oriented Community Navigation Service
Number of subjects: 0
Study 36652687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36653029 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose mumps-containing vaccine (MuCV)
Number of subjects: 105
Study 36653035 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 60
Study 36653035 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 60
Study 36653060 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 Gy of radiation to the inguinal site and concurrent cisplatin chemotherapy
Number of subjects: 157
Study 36653065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency treatment
Number of subjects: 49
Study 36653065 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency treatment
Number of subjects: 49
Study 36653167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for social anxiety
Number of subjects: 96
Study 36653167 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation
Number of subjects: 96
Study 36653241 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab (doublet therapy)
Number of subjects: 220
Study 36653533 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + CGM
Number of subjects: 481
Study 36653533 — intervention group
Group type: COMPARATOR
Intervention: CSII only
Number of subjects: 481
Study 36653533 — intervention group
Group type: COMPARATOR
Intervention: Overall (CSII only and CSII + CGM)
Number of subjects: 481
Study 36653578 — intervention group
Group type: EXPERIMENTAL
Intervention: New equations for estimated cardiorespiratory fitness (eCRF)
Number of subjects: 92
Study 36653578 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively measured cardiorespiratory fitness
Number of subjects: 92
Study 36653595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 0
Study 36653750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-derived bilateral anterior thigh thickness (BATT)
Number of subjects: 223
Study 36653768 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care strategy including rifampicin treatment daily for four months, follow-up by nursing personnel, general practitioners, specialists, and other professionals, along with transportation and food assistance.
Number of subjects: 300
Study 36653768 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid treatment received by a cohort of children between 2015 and 2018 following the standardized scheme in Colombia.
Number of subjects: 300
Study 36653786 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection phase
Number of subjects: 100
Study 36653786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase
Number of subjects: 100
Study 36653812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovolemic phlebotomy and usual care
Number of subjects: 440
Study 36653812 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 440
Study 36653848 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-vemurafenib-cobimetinib
Number of subjects: 0
Study 36653848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib-cobimetinib
Number of subjects: 0
Study 36653848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib-plus-trametinib
Number of subjects: 0
Study 36653848 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib-plus-binimetinib
Number of subjects: 0
Study 36653858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy and self-management support (12 weeks: 18 60-min group-based and 6 home-based sessions; 6 90-min group-based sessions) supervised by physiotherapists
Number of subjects: 20
Study 36653858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy and self-management support
Number of subjects: 20
Study 36653872 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-free kava
Number of subjects: 80
Study 36653872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36655056 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib per day
Number of subjects: 140
Study 36655056 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 140
Study 36655338 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMLAND (psychological mobile application)
Number of subjects: 60
Study 36655338 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 36655343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol prophylaxis targeting FVIII trough levels of 1-3%
Number of subjects: 0
Study 36655343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol prophylaxis targeting FVIII trough levels of 8-12%
Number of subjects: 0
Study 36655343 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab prophylaxis with assumed 20% FVIII equivalency
Number of subjects: 0
Study 36655470 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (50 U, 100 U, or 200 U, not to exceed 6 U/kg)
Number of subjects: 95
Study 36655712 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 54
Study 36655712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54
Study 36655731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturia group (≥2 voids/night)
Number of subjects: 10190
Study 36655731 — intervention group
Group type: EXPERIMENTAL
Intervention: NPBOO group (men)
Number of subjects: 10190
Study 36655731 — intervention group
Group type: EXPERIMENTAL
Intervention: NPOAB group (women)
Number of subjects: 10190
Study 36655731 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic NP
Number of subjects: 10190
Study 36655762 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal (MSK) flares
Number of subjects: 336
Study 36655762 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 336
Study 36655976 — intervention group
Group type: EXPERIMENTAL
Intervention: T follicular helper (Tfh) cells
Number of subjects: 0
Study 36656302 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 3014
Study 36656461 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7297089 (60 mg to 1850 mg, administered weekly by intravenous infusion)
Number of subjects: 27
Study 36656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Glycemic Control
Number of subjects: 0
Study 36656551 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 36656726 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Interpersonal Analog Scale (VIAS)
Number of subjects: 0
Study 36656726 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal behavior checklist
Number of subjects: 0
Study 36656819 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIM lifestyle intervention delivered by public health nurses
Number of subjects: 54
Study 36656819 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIM lifestyle intervention
Number of subjects: 54
Study 36656845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of left ventricular dysfunction
Number of subjects: 813
Study 36656845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of right ventricular dysfunction
Number of subjects: 813
Study 36656845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of moderate to severe valvular lesions
Number of subjects: 813
Study 36656845 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction
Number of subjects: 813
Study 36656867 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal (GI) endoscopy and biopsy specimens studied for histopathology.
Number of subjects: 110
Study 36657027 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR δ Agonism
Number of subjects: 0
Study 36657089 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 weeks postoperatively (NAC group)
Number of subjects: 699
Study 36657089 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks postoperative chemotherapy (control group)
Number of subjects: 699
Study 36657089 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (6 weeks preoperative chemotherapy)
Number of subjects: 699
Study 36657109 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept therapy
Number of subjects: 10
Study 36657323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study 36657323 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 36657324 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional hyperthermia with cisplatin added to gemcitabine (GPH)
Number of subjects: 117
Study 36657324 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 117
Study 36657520 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (active drug)
Number of subjects: 0
Study 36657520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36657659 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAD program (8-week exercise and education)
Number of subjects: 206
Study 36657659 — intervention group
Group type: COMPARATOR
Intervention: OLP (4 intra-articular saline injections over 8 weeks)
Number of subjects: 206
Study 36657661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 61
Study 36657751 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based brief smoking cessation advice, including provision of an e-cigarette and referral to local stop smoking services
Number of subjects: 972
Study 36657751 — intervention group
Group type: COMPARATOR
Intervention: Provision of contact details for local stop smoking services
Number of subjects: 972
Study 36657754 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers tested for anti-SARS-CoV-2 N antibodies
Number of subjects: 812
Study 36657754 — intervention group
Group type: COMPARATOR
Intervention: All-comer patient population tested for anti-SARS-CoV-2 N antibodies
Number of subjects: 812
Study 36657760 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training exercise programme incorporating resistance band and body weight exercises.
Number of subjects: 0
Study 36657760 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 36657801 — intervention group
Group type: EXPERIMENTAL
Intervention: Innova lateral flow tests (LFTs) using anterior nasal (AN) swabs
Number of subjects: 431
Study 36657801 — intervention group
Group type: EXPERIMENTAL
Intervention: LFTs performed on AN swabs
Number of subjects: 431
Study 36657801 — intervention group
Group type: COMPARATOR
Intervention: Paired buccal LFT swabs
Number of subjects: 431
Study 36657898 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 26
Study 36657898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 26
Study 36657898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HMB and placebo)
Number of subjects: 26
Study 36657900 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN for 5 days and then enhanced ONS until 30 days post randomization
Number of subjects: 100
Study 36657900 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN for 5 days and then standard ONS until 30 days
Number of subjects: 100
Study 36657900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care for IV fluid administration for 5 days and then enhanced ONS until 30 days
Number of subjects: 100
Study 36657900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care for IV fluid administration for 5 days and standard ONS until 30 days
Number of subjects: 100
Study 36657900 — intervention group
Group type: COMPARATOR
Intervention: Control (no PPN, no enhanced ONS)
Number of subjects: 100
Study 36657900 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN
Number of subjects: 100
Study 36657900 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 36657913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (70% cocoa), 40g offered during HD sessions, 3 times per week for two months
Number of subjects: 59
Study 36657913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 36657920 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized feeding protocol
Number of subjects: 0
Study 36657962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart valve centres (HVCs)
Number of subjects: 790
Study 36657962 — intervention group
Group type: COMPARATOR
Intervention: Satellite centres
Number of subjects: 790
Study 36658045 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac® (1 or 2 doses with an interval of 28 days)
Number of subjects: 162691
Study 36658109 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 651
Study 36658168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low resting Pd/Pa in women
Number of subjects: 1392
Study 36658168 — intervention group
Group type: COMPARATOR
Intervention: High resting Pd/Pa in women
Number of subjects: 1392
Study 36658168 — intervention group
Group type: COMPARATOR
Intervention: CFR assessment in women
Number of subjects: 1392
Study 36658168 — intervention group
Group type: COMPARATOR
Intervention: CFR in men
Number of subjects: 1392
Study 36658374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Jet Ventilation (HFJV)
Number of subjects: 60
Study 36658380 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase heart rate variability (HRV) biofeedback (Osc+)
Number of subjects: 165